A retrospective analysis of iv ketamine outcome on hospitalisations in an unselected psychiatric sample.
Acta neuropsychiatrica – April 25, 2024
Source: PubMed
Summary
Ketamine, a promising antidepressive agent, shows potential in treating severe mood disorders. In a clinical analysis of 46 patients with treatment-resistant depression, ketamine therapy reduced depressive symptoms in about one-third of participants. While the treatment demonstrated effectiveness in complex cases, it didn't significantly reduce hospital stays. This highlights ketamine's role as one tool in managing severe psychiatric conditions.
Abstract
This study aims to explore the outcome with iv ketamine treatment in a real-world clinical setting, primarily measured as posttreatment days hospitalised. The psychiatric medical records of 46 patients having received iv ketamine on a psychiatric treatment indication between 2015 and 2018 were retrospectively examined. Analysis comparing the number and duration of hospital admissions before and after ketamine treatment as well as logistic regression analysis to investigate clinical predictors of effectiveness, were performed. To assess patients' severity of depressed symptoms records were screened for MADRS-S scores. No significant difference between pre- and posttreatment hospital days (p = 0.170), or number of hospitalisations (p = 0.740) were found. The response rate was 31% and remission rate 21%. None of the predictors showed statistical significance in the logistic model. Iv ketamine treatment showed effectiveness in reducing depressive symptoms even with complex patients in a real-world clinical setting. However, this did not translate to a reduction in hospitalisation. Highlighting the multifaceted challenges posed when implementing iv ketamine treatment in clinical practice.